Full-Time
Associate Director
Biostatistics
Rhythm Pharmaceuticals
201-500 employees
Commercializes MC4R-targeted therapies for rare obesity
Compensation Overview
$160k - $240k/yr
Boston, MA, USA
Hybrid
Hybrid work requires attendance at the Boston office based on department and business needs; some travel may be required.
Master's, PhD
 Biology & Biotech (1) |
|---|
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
- An MS in Statistics, Biostatistics, or a related discipline with approximately 8 or more years of relevant experience, or a PhD in Statistics, Biostatistics, or a related quantitative discipline with approximately 5 or more years of relevant clinical trial experience in biopharma, biotech, or CRO settings.
- Strong understanding of statistical concepts and clinical trial methodologies, with the ability to apply them to practical development and analysis challenges.
- Knowledge of the drug development process and experience supporting clinical studies across one or more phases of development.
- Proficiency with SAS and R.
- Familiarity with CDISC requirements, including SDTM and ADaM standards.
- Ability to manage multiple priorities, projects, and timelines while maintaining attention to quality and detail.
- Ability to work independently within established strategic direction, collaborate across functions, and adapt to evolving priorities in a fast-paced biotech environment.
- Serve as the statistical lead for assigned clinical studies or defined program activities, contributing to clinical development plans, study design, sample size and power calculations, protocols, statistical analysis plans, tables, listings, and figures, data analyses, and interpretation of results.
- Collaborate with cross-functional partners to support study strategy, execution, and decision-making, ensuring statistical considerations are incorporated into clinical plans and deliverables.
- Prepare and review statistical content for protocols, clinical study reports, integrated summaries of safety and efficacy, and other submission-related or study-level documents.
- Oversee statistical vendors for assigned deliverables, including review, validation, and quality control of outputs to ensure accuracy, consistency, and compliance with company standards.
- Work with statistical programmers to review key efficacy and safety outputs, support dry runs and quality control, identify data or analysis issues, and drive timely resolution.
- Support interim analyses, Data and Safety Monitoring Board meetings, ad hoc analyses, and other statistical activities required to advance clinical program needs.
- Contribute to statistical components of global regulatory submissions, including relevant sections of Common Technical Document Modules 2.5, 2.7, and 5.
- Support the presentation of statistical analyses and results in regulatory submissions and briefing materials, including Investigational New Drug applications, New Drug Applications, Biologics License Applications, Marketing Authorisation Applications, and Japanese New Drug Applications.
- Partner with data management on case report forms, data management plans, edit checks, data review activities, and related processes that support high-quality analysis outputs.
- Contribute to departmental standards, templates, process improvements, and practical solutions that enhance quality, efficiency, and inspection readiness.
- Experience with sample size software such as EAST.
- Experience contributing to Investigational New Drug, New Drug Application, Biologics License Application, Marketing Authorisation Application, Japanese New Drug Application, or other regulatory submission deliverables.
- Excellent communication, presentation, and report-writing skills, including the ability to explain complex statistical concepts clearly to cross-functional and non-statistical audiences.
Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine and genetic obesity disorders. Its lead drug, IMCIVREE (setmelanotide), is an MC4R agonist that helps restore signaling in the melanocortin-4 pathway to regulate hunger and energy use. The company earns revenue primarily from global IMCIVREE sales and reinvests in research, development, and commercialization. Its aim is to broaden MC4R-targeted treatments for underserved patients and advance additional candidates like bivamelagon and RM-718 through clinical development.
Company Size
201-500
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
2008
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 product revenue hit $71.3 million, up 19% sequentially.
- More than 400 acquired-HO start forms came from roughly 300 prescribers by June 30, 2026.
- AJ Joshi became chief medical officer on August 17, 2026, strengthening late-stage execution.
What critics are saying
- Rhythm depends on IMCIVREE; August 2026 revenue still came entirely from one drug.
- RM-718 and bivamelagon must succeed after 2026 data; failure leaves no next growth engine.
- Hypothalamic obesity launches in Japan and Europe need reimbursement speed; delays hit 2027 demand.
What makes Rhythm Pharmaceuticals unique
- Rhythm owns the only approved MC4R franchise for rare genetic obesity, built since 2008.
- IMCIVREE won Japan MHLW approval on August 24, 2026, extending global rare-obesity reach.
- Rhythm published a Bardet-Biedl diagnostic algorithm, improving patient identification for prescribers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Performance Bonus
Company Equity
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 8%2 year growth
↑ 2%Stanley Druckenmiller's Duquesne Family Office disclosed new positions in over 40 stocks in its second quarter 13F filing. Notable healthcare investments included 203,618 shares of Rhythm Pharmaceuticals worth $22.6 million and 356,600 shares of Definium Therapeutics worth $16.8 million. Rhythm Pharmaceuticals develops treatments for hypothalamic obesity, currently the only approved drug for this condition. The company estimates approximately 10,000 US patients have acquired hypothalamic obesity, with similar numbers in Europe and 5,000 to 8,000 in Japan. Second-quarter revenue increased 47% year over year, whilst US revenue jumped 38% sequentially. The company remains unprofitable despite revenue growth and held $330.9 million in cash at quarter end, expected to fund operations for at least 24 months.
Rhythm Pharmaceuticals has received approval from Japan's Ministry of Health, Labour and Welfare for IMCIVREE (setmelanotide) to treat patients with acquired hypothalamic obesity (HO). This marks the first therapy approved in Japan for this condition. The approval was supported by the Phase 3 TRANSCEND trial involving 142 patients, including a Japanese cohort. The study met its primary endpoint with an 18.8% placebo-adjusted reduction in body mass index. Rhythm estimates 5,000 to 8,000 people are living with acquired HO in Japan. The company expects to launch IMCIVREE before the end of 2026, pending final pricing determination. Acquired HO is characterised by accelerated weight gain following hypothalamic injury, often resulting from craniopharyngioma, astrocytoma, or other hypothalamic-pituitary tumours.
Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi as Chief Medical Officer, effective 17 August. Dr Joshi brings over 20 years of experience spanning drug discovery, pivotal trials, regulatory processes and lifecycle management. Dr Joshi joins from Soleno Therapeutics, where he served as Chief Development Officer. He previously held the Chief Medical Officer position at Neurona Therapeutics and executive roles at Atara Biotherapeutics. His career also includes leadership positions at Allergan Medical, Synageva BioPharma, and Genzyme. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the US and Europe for treating certain forms of obesity. The company is advancing next-generation MC4R agonists through late-stage development.
Rhythm Pharmaceuticals announced that the UK's Medicines and Healthcare products Regulatory Agency has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include treatment of obesity and control of hunger in adults and children aged 4 and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO. The approval is based on results from the Phase 3 TRANSCEND trial, which met its primary endpoint with a statistically significant 19.8% placebo-adjusted reduction in body mass index. The global trial enrolled 120 patients. IMCIVREE initially received marketing authorisation in the UK in 2021 for treatment of obesity in patients with POMC, PCSK1 or LEPR deficiency, with subsequent expansions for other rare obesity conditions.
Rhythm Pharmaceuticals reported preliminary results showing its experimental weekly injectable drug RM-718 helped reduce body weight in patients with acquired hypothalamic obesity, a rare condition caused by brain damage from tumour surgery or treatment. The Boston-based company's shares rose 5% in premarket trading. Among 11 enrolled patients, seven who completed 16 weeks of treatment saw their body mass index fall by an average of 11.6%. The drug works by activating the MC4R brain receptor, which controls hunger and metabolism. Two patients discontinued treatment due to side effects including nausea and injection site problems. Rhythm also sells setmelanotide for the same condition under the brand name Imcivree. Separately, the company reported second-quarter revenue of $71.3 million, up 46.9% from $48.5 million a year earlier.